Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 36 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Keyword is Receptor, ErbB-2 [Clear All Filters]
Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome..
Clin Breast Cancer. 19(2), 113-125.e4.
(2019).
(2018).
(2016).
Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study..
J Transl Med. 13, 171.
(2015). Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer..
J Natl Cancer Inst. 107(8),
(2015). p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab..
Pathol Oncol Res. 21(2), 273-82.
(2015). PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients..
Cancer Chemother Pharmacol. 75(6), 1289-301.
(2015). Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes..
Cell Oncol (Dordr). 38(2), 155-64.
(2015). Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17..
PLoS One. 9(8), e103707.
(2014). Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence..
Breast. 23(6), 829-35.
(2014). EGFR and HER2 exert distinct roles on colon cancer cell functional properties and expression of matrix macromolecules..
Biochim Biophys Acta. 1840(8), 2651-61.
(2014). HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma..
Arch Gynecol Obstet. 290(6), 1231-7.
(2014).
(2014).
(2014). Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays..
Anticancer Res. 33(5), 2139-45.
(2013).
(2013). HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients..
Br J Cancer. 108(3), 668-75.
(2013). Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial..
PLoS One. 8(7), e69256.
(2013). Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)..
PLoS One. 8(7), e70634.
(2013). Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research..
Virchows Arch. 462(2), 141-54.
(2013). 19p13.1 is a triple-negative-specific breast cancer susceptibility locus..
Cancer Res. 72(7), 1795-803.
(2012). Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel..
PLoS One. 7(6), e37946.
(2012). Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel..
Anticancer Res. 32(10), 4569-80.
(2012). HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy..
J Transl Med. 10, 10.
(2012). Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression..
Clin Breast Cancer. 12(3), 183-93.
(2012).